Quanterix Corporation is a company that aids in the development of new generation molecular diagnostic tests owing to its groundbreaking Single Molecule Array (SiMoA™) technology.
In an online study published in the Journal of Immunological Methods, Quanterix announced the findings of a lead study that quantified inflammation-causing biomarkers in patients with Crohn’s disease. According to the results, Quanterix’s high sensitivity digital ELISA facilitated the accurate estimation of low abundance cytokines enabling the detection of considerable changes in patients both before and after initial therapy.
Corresponding study author, David Duffy, Ph.D., explained: “Quanterix’s digital ELISA enabled physiologically relevant concentrations of two important cytokines, TNF-alpha and IL-6, to be measured in plasma from all patient samples tested. Previous studies have not been able to quantify these biomarkers in all patients due to insufficient sensitivity. The inherent sensitivity of this technology also made it possible, for the first time, to accurately quantify changes in protein levels during the course of anti-TNF-alpha therapy. This work has important implications for patient management, including the ability to provide a quantitative index for how an individual is responding to therapy.”
Quanterix’s Executive Chairman, Martin Madaus, Ph.D., said: “Our collaboration with the Mayo Clinic is another example that highlights how unprecedented sensitivity enables important contributions to life science research and in vitro diagnostics. Although larger studies will be needed to fully understand the potential utility of cytokine measurements in the diagnosis of inflammatory diseases such as Crohn’s, these results provide some indication of how sensitive and precise protein measurements enabled by SiMoA could be used clinically.”